Evidence map›Paper›PMID 35811518›Full record

Trial reportJournal of Alzheimer's disease : JAD2022

Precision Medicine Approach to Alzheimer's Disease: Successful Pilot Project.

Kat Toups, Ann Hathaway, Deborah Gordon, Henrianna Chung, Cyrus Raji, Alan Boyd, Benjamin D Hill, Sharon Hausman-Cohen, Mouna Attarha, Won Jong Chwa and 2 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of Alzheimer's disease : JAD, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05894954 (EVANTHEA TRIAL), which is not on this map. Cited by 41 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05894954 phase3completednot on this mapstarted 2023, after this paper: background citation

EVANTHEA TRIAL: A Pragmatic, Randomized, Controlled Trial to Evaluate the Effectiveness of a Precision Medicine Treatment Approach for Early Dementia and Mild Cognitive Impairment

TypeinterventionalSponsorAlzheimer's Prevention and Reversal Project, Inc.Ran2023 to 2026Enrolled73ConditionsMild Cognitive Impairment, Dementia, MildArmsPrecision Medicine Approach, Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises, Standard-of-Care, Lifestyle including diet, exercise, stress management
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 1 country.

Kat ToupsBay Area Wellness, Walnut Creek, CA, USA.
Ann HathawayDr. Ann Hathaway, San Rafael, CA, USA.
Deborah GordonNorthwest Memory Center, Ashland, OR, USA.
Henrianna ChungQuesgen Systems, Burlingame, CA, USA.
Cyrus RajiDepartment of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
Alan BoydCNS Vital Signs, Morrisville, NC, USA.
Benjamin D HillDepartment of Psychology, University of South Alabama, Mobile, AL, USA.
Sharon Hausman-CohenIntellxxDNA, Austin, TX, USA.
Mouna AttarhaPosit Science, San Francisco, CA, USA.
Won Jong ChwaDepartment of Radiology, St. Louis University, St. Louis, MO, USA.
Michael JarrettQuesgen Systems, Burlingame, CA, USA.
Dale E BredesenDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
Ashland (United States) · USCalifornia Wellness Foundation · USCenter for Neurorehabilitation Services · USIntel (United States) · USPosit Science (United States) · USSaint Louis University · USUniversity of California, Los Angeles · USUniversity of South Alabama · USWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEffective therapeutics for Alzheimer's disease are needed. However, previous clinical trials have pre-determined a single treatment modality, such as a drug candidate or therapeutic procedure, which may be unrelated to the primary drivers of the neurodegenerative process. Therefore, increasing data set size to include the potential contributors to cognitive decline for each patient, and addressing the identified potential contributors, may represent a more effective strategy.

objectiveTo determine whether a precision medicine approach to Alzheimer's disease and mild cognitive impairment is effective enough in a proof-of-concept trial to warrant a larger, randomized, controlled clinical trial.

methodsTwenty-five patients with dementia or mild cognitive impairment, with Montreal Cognitive Assessment (MoCA) scores of 19 or higher, were evaluated for markers of inflammation, chronic infection, dysbiosis, insulin resistance, protein glycation, vascular disease, nocturnal hypoxemia, hormone insufficiency or dysregulation, nutrient deficiency, toxin or toxicant exposure, and other biochemical parameters associated with cognitive decline. Brain magnetic resonance imaging with volumetrics was performed at baseline and study conclusion. Patients were treated for nine months with a personalized, precision medicine protocol, and cognition was assessed at t = 0, 3, 6, and 9 months.

resultsAll outcome measures revealed improvement: statistically significant improvement in MoCA scores, CNS Vital Signs Neurocognitive Index, and Alzheimer's Questionnaire Change score were documented. No serious adverse events were recorded. MRI volumetrics also improved.

conclusionBased on the cognitive improvements observed in this study, a larger, randomized, controlled trial of the precision medicine therapeutic approach described herein is warranted.

Indexed as

Alzheimer DiseaseCognitive DysfunctionCognitionHumansPilot ProjectsPrecision MedicineClinical trialmild cognitive impairmentMRI volumetricsneurodegenerationsystems medicine

Identifiers

PMID35811518
PMCPMC9484109
OpenAlexW4284683871

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.